Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSMNYSE / NASDAQHealthcareSmall cap

$129.36-$6.32 (-4.7%)

Last close · Data as of Nov 20, 2026

Market cap
$11.9B
P/E
-65.0x
EV / EBITDA
-70.2x
Revenue
$638.5M
Net margin
-28.7%
ROCE
-54.4%

-9.7% over the last year

Axsome Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-18.9%
3M
-37.8%
6M
-43.9%
1Y
-9.7%
5Y
+261.3%

52-week range

Day change -$6.32 (-4.7%) from $136 to $129 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AXSM, bought on each weekday since 2021.

News & filings

What Axsome Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 183 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 65.5% in fiscal 2025.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

Read moreShow less

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Sector
Healthcare
Shares outstanding
50.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$11.9B
P/E
-65.0x
P/B
134.9x
EV / EBITDA
-70.2x
EV / Sales
18.5x
P/S
18.7x
52-week high
$255.17
52-week low
$129.36

Profitability

Operating margin
-26.5%
Net margin
-28.7%
EBITDA margin
-26.3%
ROE
-207.5%
ROCE
-54.4%
ROA
-26.6%
Asset turnover
0.93

Growth

Revenue
$638.5M
Revenue growth, 1Y
65.5%
Revenue CAGR, 3Y
133.7%
Net profit growth, 1Y
-36.2%
Free cash flow
-$93.9M

Solvency

Current ratio
1.55
Debt / Equity
2.47
Debt / Assets
0.32
CFO / Net profit
0.51
Cash / Market cap
2.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$638.5M
Cost of revenue$47.5M
Gross profit$591.0M
Operating expenses$760.3M
Research and development$183.3M
Selling, general and administrative$570.6M
Operating income-$169.2M
Interest and other-$14.5M
Pretax income-$183.7M
Tax and other-$530.0k
Net income-$183.2M

Revenue and net profit

Revenue grew 65.5% in FY2025; net profit is the dashed line.

Axsome Therapeutics, Inc. revenue and net profit by fiscal year
Axsome Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$50.0M-$187.1M
FY2023$270.6M-$239.2M
FY2024$385.7M-$287.2M
FY2025$638.5M-$183.2M

Cash flows

FY2025: -$93.4M from operations, -$93.9M free after investment (dashed).

Axsome Therapeutics, Inc. operating and free cash flow by fiscal year
Axsome Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$116.5M-$117.2M
FY2023-$145.1M-$145.7M
FY2024-$128.4M-$128.7M
FY2025-$93.4M-$93.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$638.5M+65.5%1Y
EBITDA
-$168.1M
Net profit
-$183.2M
Cash from operations
-$93.4M
Free cash flow
-$93.9M
Revenue CAGR, 3Y
133.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$638.5M-$168.1M-$183.2M-$93.9M-207.5%+65.5%-36.2%

Monthly returns

Month-by-month returns of AXSM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$689.8M
Liabilities$601.5M
Equity$88.3M
Paid-in capital$1.4B
Retained earnings-$1.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AXSM highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Axsome Therapeutics, Inc. (this company)18.5x

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Axsome Therapeutics, Inc.AXSMthis company$11.9B-65.0x134.9x-207.5%-70.2x
BridgeBio Pharma, Inc.BBIO$13.2B-18.2x-6.3x34.7%-26.4x
Madrigal Pharmaceuticals, Inc.MDGL$11.4B-39.4x18.9x-47.8%-43.5x
Arrowhead Pharmaceuticals, Inc.ARWR$10.6B-6491.0x22.7x-0.3%65.9x
Cytokinetics, IncorporatedCYTK$9.8B——119.0%—
The Ensign Group, Inc.ENSG$9.6B27.9x4.3x15.4%19.9x
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
Praxis Precision Medicines, Inc.PRAX$7.4B-24.3x8.4x-34.5%-21.5x
Peer median—-21.7x5.9x7.5%-24.0x

Year-to-date ROI

AXSM since 1 January, against earlier years.

Historical volatility

AXSM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Axsome Therapeutics, Inc. operating margin by fiscal year
Axsome Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-352.7%
FY2023-67.6%
FY2024-65.5%
FY2025-26.5%
LineFY2025
Cost of revenueCost Of Revenue$47.5M
Gross profitGross Profit$591.0M
Operating expensesOperating Expense$760.3M
Research and developmentResearch And Development$183.3M
Depreciation and amortisationDepreciation And Amortization In Income Statement$6.4M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$6.4M
Amortization$6.4M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$6.4M
Total expensesTotal Expenses$807.7M
Pretax incomePretax Income-$183.7M

Learn while you research

Academy chapters picked for Axsome Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing66% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Leverage RatiosDebt/Equity of 2.47 is elevated, understand what that means for solvency.6 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →